Vanda Pharmaceuticals Inc.

NasdaqGM:VNDA Stock Report

Market Cap: US$278.2m

Vanda Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:VNDA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Mar 25BuyUS$50,150Mihael PolymeropoulosIndividual10,000US$5.02
05 Mar 25BuyUS$50,200Mihael PolymeropoulosIndividual10,000US$5.03
03 Mar 25BuyUS$47,050Mihael PolymeropoulosIndividual10,000US$4.71
28 Feb 25BuyUS$47,600Mihael PolymeropoulosIndividual10,000US$4.76
27 Feb 25BuyUS$47,600Mihael PolymeropoulosIndividual10,000US$4.76
26 Feb 25BuyUS$47,650Mihael PolymeropoulosIndividual10,000US$4.78
25 Feb 25BuyUS$44,640Mihael PolymeropoulosIndividual10,000US$4.46
21 Feb 25BuyUS$8,779Kevin MoranIndividual2,000US$4.39
14 Nov 24SellUS$25,863Stephen MitchellIndividual5,000US$5.17
29 Jul 24SellUS$13,327Kevin MoranIndividual2,251US$5.92

Insider Trading Volume

Insider Buying: VNDA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VNDA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,825,3544.84%
Hedge Funds3,853,7996.61%
General Public15,591,82626.7%
Institutions36,045,06561.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 56.35% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.06%
BlackRock, Inc.
4,699,280US$22.4m-48.4%no data
6.61%
Renaissance Technologies LLC
3,853,799US$18.4m-3.93%0.03%
6.01%
The Vanguard Group, Inc.
3,506,287US$16.7m-3.44%no data
4.27%
Dimensional Fund Advisors LP
2,488,519US$11.9m10.1%no data
4.04%
Tang Capital Management, LLC
2,353,307US$11.2m0%0.7%
3.94%
Mihael Polymeropoulos
2,295,731US$11.0m83.8%no data
3.26%
Acadian Asset Management LLC
1,900,002US$9.1m0%0.02%
2.49%
Geode Capital Management, LLC
1,450,310US$6.9m1.72%no data
2.03%
State Street Global Advisors, Inc.
1,183,863US$5.6m1.6%no data
1.78%
Schroder Investment Management Limited
1,038,020US$5.0m0%no data
1.66%
Morgan Stanley, Investment Banking and Brokerage Investments
970,601US$4.6m225%no data
1.41%
Connor, Clark & Lunn Investment Management Ltd.
819,382US$3.9m4.92%0.02%
1.25%
Federated Hermes, Inc.
726,619US$3.5m1.37%0.01%
1.15%
Millennium Management LLC
668,693US$3.2m67.4%no data
1.1%
PGIM, Inc.
640,780US$3.1m-0.28%no data
0.96%
Charles Schwab Investment Management, Inc.
558,446US$2.7m-6.33%no data
0.87%
Northern Trust Global Investments
507,442US$2.4m1.25%no data
0.86%
Goldman Sachs Asset Management, L.P.
500,912US$2.4m-8.68%no data
0.81%
Jacobs Levy Equity Management Inc
470,726US$2.2m-67.1%0.01%
0.67%
Monaco Asset Management S.A.M.
392,262US$1.9m92.8%0.74%
0.65%
Citadel Advisors LLC
381,085US$1.8m168%no data
0.65%
Krensavage Asset Management, LLC
378,762US$1.8m-8.66%1.1%
0.63%
Eaton Vance Management
369,902US$1.8m16.6%no data
0.61%
SEI Investments Management Corporation
357,059US$1.7m-4.11%no data
0.6%
Wellington Management Group LLP
348,846US$1.7m12.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 09:26
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vanda Pharmaceuticals Inc. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Olivia BrayerBofA Global Research
Difei YangBrean Capital